Want to see AURX full AI Analyst Report?
Top Page
Nuo Therapeutics
(OTC:AURX)
Select Model
Select Model
Rating:52Neutral
Price Target:
$1.50
▲(40.19% Upside)
Action:Reiterated
Date:10/07/26
The score is held back primarily by weak financial fundamentals—ongoing losses, negative cash flow, and a strained balance sheet with negative equity. Technicals are relatively supportive with improving momentum, while valuation remains constrained by negative earnings. The recent financing provides liquidity but adds high-cost debt and dilution-related overhang.
Positive Factors
Revenue Growth and Gross Margin
Strong top-line growth alongside a healthy gross margin indicates improving commercial traction and meaningful economics on sales. If maintained, this combination can support reinvestment in commercialization and gradually improve operating leverage as the company scales its wound-care business.
Negative Factors
Persistent Unprofitability
The company has not yet demonstrated sustained profitability, with materially negative operating and net margins despite improving results from earlier years. Persistent losses can constrain reinvestment, weaken financial flexibility, and make future growth dependent on continued access to outside capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth and Gross Margin
Strong top-line growth alongside a healthy gross margin indicates improving commercial traction and meaningful economics on sales. If maintained, this combination can support reinvestment in commercialization and gradually improve operating leverage as the company scales its wound-care business.
Read all positive factors
Nuo Therapeutics (AURX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$62.48M
Dividend YieldN/A
Average Volume (3M)2.93K
Price to Earnings (P/E)―
Beta (1Y)-0.56
Revenue Growth166.61%
EPS Growth21.09%
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding48,433,777
10 Day Avg. Volume3,882
30 Day Avg. Volume2,934
Financial Highlights & Ratios
PEG Ratio-10.00
Price to Book (P/B)-97.44
Price to Sales (P/S)28.13
P/FCF Ratio-81.78
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue9.20
Enterprise Value/Gross Profit14.35
Enterprise Value/Ebitda-30.67
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nuo Therapeutics Business Overview & Revenue Model
Company Description
Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacit...
Nuo Therapeutics Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
22
Negative
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.20M | 3.31M | 1.37M | 608.52K | 112.25K | 0.00 |
| Gross Profit | 3.33M | 2.22M | 1.06M | 482.43K | 93.04K | 0.00 |
| EBITDA | -1.56M | -2.36M | -2.36M | -3.06M | -3.10M | 0.00 |
| Net Income | -2.01M | -2.51M | -2.32M | -3.17M | -3.03M | -90.67K |
Balance Sheet | ||||||
| Total Assets | 2.63M | 1.85M | 1.19M | 1.88M | 3.05M | 149.93K |
| Cash, Cash Equivalents and Short-Term Investments | 449.32K | 548.95K | 283.71K | 928.68K | 2.05M | 148.43K |
| Total Debt | 1.50M | 597.35K | 164.21K | 255.59K | 335.04K | 0.00 |
| Total Liabilities | 4.16M | 2.80M | 675.80K | 838.73K | 856.02K | 672.47K |
| Stockholders Equity | -1.54M | -956.56K | 513.71K | 1.04M | 2.19M | -522.54K |
Cash Flow | ||||||
| Free Cash Flow | -2.45M | -1.14M | -2.39M | -3.18M | -3.77M | -13.00K |
| Operating Cash Flow | -2.15M | -864.97K | -2.23M | -3.17M | -3.71M | -13.00K |
| Investing Cash Flow | -297.08K | -274.76K | -154.96K | -7.24K | -59.99K | 0.00 |
| Financing Cash Flow | 2.58M | 1.40M | 1.74M | 2.00M | 4.46M | 1.37T |
Nuo Therapeutics Technical Analysis
Neutral
1.07
Price Trends
1.16
Positive
1.07
Positive
1.28
Positive
Market Momentum
0.03
Positive
58.11
Neutral
81.11
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AURX, the sentiment is Neutral. The current price of 1.07 is below the 20-day moving average (MA) of 1.29, below the 50-day MA of 1.16, and below the 200-day MA of 1.28, indicating a bullish trend. The MACD of 0.03 indicates Positive momentum. The RSI at 58.11 is Neutral, neither overbought nor oversold. The STOCH value of 81.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AURX.
Nuo Therapeutics Risk Analysis
Nuo Therapeutics disclosed 40 risk factors in its most recent earnings report. Nuo Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nuo Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $62.48M | -31.10 | 187.41% | ― | 166.61% | 21.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $48.02M | -3.94 | 83.45% | ― | ― | 15.65% | |
48 Neutral | $43.57M | -2.28 | -82.87% | ― | -100.00% | 72.25% | |
48 Neutral | $46.04M | -1.21 | 248.50% | ― | ― | 36.06% | |
44 Neutral | $23.61M | -0.43 | -98.86% | ― | ― | -33.93% | |
40 Underperform | $15.66M | -0.25 | -108.72% | ― | 2.15% | 17.34% |
* Healthcare Sector Average
AURX
Nuo Therapeutics
1.29
-1.21
-48.40%
IMMP
Immutep
3.20
-37.60
-92.16%
INMB
Inmune Bio
1.57
-0.35
-18.23%
TCRX
TScan Therapeutics
0.23
-2.29
-90.83%
INKT
MiNK Therapeutics
9.41
-5.36
-36.29%
TVGN
Tevogen Bio Holdings
7.07
-27.99
-79.84%
Nuo Therapeutics Corporate Events
Private Placements and Financing
Nuo Therapeutics Secures Second Loan Funding with Warrants
Positive
Oct 6, 2026
On October 6, 2026, Nuo Therapeutics, Inc. completed the second funding under its amended loan and security agreement, securing $325,000 and bringing total proceeds under the facility to $2,000,000, consistent with its previously disclosed commitm...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.